文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

单次呼吸一氧化碳弥散功能的跨次变异

Intersession Variability in Single-Breath Diffusing Capacity of Carbon Monoxide.
PubMed 文献 · Chest · 2025-09-16
一句话结论稳定肺功能患者中Dlco跨次变异可超过常规阈值,研究基于85th与95th百分位提出稳定、可能变化、确定变化三级分级及基线Dlco特异性混合阈值。

该队列研究分析5,069例肺功能稳定(FEV1与FVC变化均<5%)且至少有2次血红蛋白校正Dlco测量的患者,评估绝对差值、预计值百分比绝对差值与相对百分比差值三种变异指标。Dlco跨次变异超过常规阈值,三种指标的90th百分位分别为3.5 mL/min/mm Hg、15%和21%。基线Dlco较高、血红蛋白较低、男性及限制性模式与更大绝对变异相关,但仅解释总变异的一小部分(R2=0.114)。重测信度优秀,但存在显著异方差(Spearman ρ=0.241,P<.001),提示测量变异随Dlco幅度系统性增大。研究基于85th与95th百分位建立三级分级系统,并提出基线Dlco特异性混合阈值(<50%预计值时≤2.5 mL/min/mm Hg;≥50%预计值时≤3.5 mL/min/mm Hg)。

要点

  • 稳定肺功能患者Dlco跨次变异的90th百分位:绝对差值3.5 mL/min/mm Hg、预计值百分比差值15%、相对百分比差值21%。
  • 基线Dlco较高、血红蛋白较低、男性及限制性模式与更大绝对变异相关,但仅解释总变异的一小部分(R2=0.114)。
  • 重测信度优秀,但存在显著异方差(Spearman ρ=0.241,P<.001),测量变异随Dlco幅度系统性增大,单一阈值无法在所有基线Dlco水平上最优。
  • 研究基于85th与95th百分位建立稳定、可能变化、确定变化三级分级系统。
  • 基线Dlco特异性混合阈值:<50%预计值时≤2.5 mL/min/mm Hg,≥50%预计值时≤3.5 mL/min/mm Hg,在不同Dlco类别间表现更一致。

适用人群与场景

  • 肺功能稳定(FEV1与FVC变化均<5%)且至少有2次血红蛋白校正Dlco测量的患者,共5,069例。

诊断标准与关键阈值

  • 三级分级系统基于85th与95th百分位阈值,分为稳定、可能变化、确定变化三级。
  • 基线Dlco特异性混合阈值:<50%预计值时≤2.5 mL/min/mm Hg;≥50%预计值时≤3.5 mL/min/mm Hg。

研究设计与关键结果

  • 队列研究分析5,069例肺功能稳定(FEV1与FVC变化均<5%)且至少有2次血红蛋白校正Dlco测量的患者,评估绝对差值、预计值百分比绝对差值与相对百分比差值三种变异指标。
  • Dlco跨次变异超过常规阈值,90th百分位:绝对差值3.5 mL/min/mm Hg、预计值百分比差值15%、相对百分比差值21%。
  • 基线Dlco较高、血红蛋白较低、男性及限制性模式与更大绝对变异相关,但仅解释总变异的一小部分(R2=0.114)。
  • 重测信度优秀,但存在显著异方差(Spearman ρ=0.241,P<.001),测量变异随Dlco幅度系统性增大。
  • 基于85th与95th百分位建立三级分级系统(稳定、可能变化、确定变化)。
  • 基线Dlco特异性混合阈值(<50%预计值时≤2.5 mL/min/mm Hg;≥50%预计值时≤3.5 mL/min/mm Hg)在不同Dlco类别间表现更一致。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 解读系列Dlco测量时,可参考本研究基于85th与95th百分位的三级分级系统区分稳定、可能变化与确定变化。
  • 选择变异指标会影响变化解读,尤其在不同基线Dlco水平之间。
  • 基线Dlco<50%预计值时采用≤2.5 mL/min/mm Hg、≥50%预计值时采用≤3.5 mL/min/mm Hg的混合阈值,在不同Dlco类别间表现更一致。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Diffusing capacity for carbon monoxide (Dlco) is a critical measurement for diagnosing and monitoring cardiorespiratory diseases, but its clinical utility is limited by measurement variability. Clinical guidelines lack evidence-based thresholds for distinguishing significant changes from normal variability.

RESEARCH QUESTION: What is the magnitude and determinants of Dlco intersession variability in routine clinical practice, and what evidence-based thresholds can guide interpretation of serial measurements?

STUDY DESIGN AND METHODS: This cohort study analyzed data from 5,069 patients with stable spirometry-defined as < 5% change in both FEV1 and FVC-and at least 2 hemoglobin-adjusted Dlco measurements. Three variability metrics were assessed: absolute difference (mL/min/mm Hg), absolute difference in percent predicted, and relative percentage difference.

RESULTS: Dlco demonstrated substantial intersession variability that exceeded conventional thresholds, with 90th percentile values of 3.5 mL/min/mm Hg (absolute), 15% (percent predicted), and 21% (relative percentage). Higher baseline Dlco, lower hemoglobin, male sex, and restrictive patterns were associated with greater absolute variability, but these factors only explained a fraction of total observed variability (R2 = 0.114). Test-retest reliability was excellent, but significant heteroscedasticity (Spearman ρ = 0.241, P < .001) demonstrated that measurement variability increases systematically with Dlco magnitude, explaining why no single threshold performs optimally across all baseline Dlco levels. A 3-tier grading system was developed based on the 85th and 95th percentile thresholds (stable, possible change, and definite change). A novel hybrid approach using baseline Dlco-specific absolute thresholds (≤ 2.5 mL/min/mm Hg for < 50% predicted; ≤ 3.5 mL/min/mm Hg for ≥ 50% predicted) demonstrated more consistent performance across Dlco categories.

INTERPRETATION: In this study, Dlco was shown to exhibits substantial intersession variability in clinical settings, exceeding commonly recognized levels. The choice of variability metric influenced how changes are interpreted, especially across different baseline Dlco values. The evidence-based thresholds and 3-tier classification system established in this study provide practical tools for distinguishing clinically significant Dlco changes from normal measurement variability.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Yadav H, Scanlon PD, Aksamit TR, et al. Intersession Variability in Single-Breath Diffusing Capacity of Carbon Monoxide. Chest. 2025. PMID: 40967368. doi:10.1016/j.chest.2025.09.006

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。